Buy Rating Reaffirmed for Omega Therapeutics on Strong Clinical and Financial Performance
Novo Nordisk ties up with Metaphore to develop new obesity drugs
Omega Therapeutics Presents New Preclinical Data at ASGCT 2024 Demonstrating Tunable and Durable Upregulation of Gene Expression with Epigenomic Controllers
Omega Therapeutics Presents New Preclinical Data at ASGCT 2024 Demonstrating Tunable and Durable Upregulation of Gene Expression with Epigenomic Controllers
Omega Therapeutics First Quarter 2024 Earnings: Revenues Beat Expectations, EPS In Line
Buy Rating Affirmed for Omega Therapeutics Amid Strong Financials and Promising OTX-2002 Clinical Trials
Omega Therapeutics, Inc. Reports Q1 Loss, Tops Revenue Estimates
Omega Therapeutics, Inc. (OMGA) Reports Q1 Loss, Tops Revenue Estimates
Omega Therapeutics, Inc. (OMGA) Reports Q1 Loss, Tops Revenue Estimates
Omega Therapeutics Reports First Quarter 2024 Financial Results and Highlights Recent Company Progress
Omega Therapeutics GAAP EPS of -$0.36, revenue of $2.36M
Omega Therapeutics Reports First Quarter 2024 Financial Results and Highlights Recent Company Progress
Should You Invest in Novo Nordisk (NVO) Ahead of Q1 Earnings?
MXL, COLM and SPSC are among after hour movers
MXL, COLM and SPSC are among after hour movers
Omega Therapeutics, Inc. (OMGA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Omega Therapeutics to Present New Preclinical Data on Epigenomic Upregulation at the American Society of Gene and Cell Therapy 27th Annual Meeting
Omega Therapeutics to Present New Preclinical Data on Epigenomic Upregulation at the American Society of Gene and Cell Therapy 27th Annual Meeting
Omega Therapeutics to Present New Preclinical Data on Epigenomic Upregulation at the American Society of Gene and Cell Therapy 27th Annual Meeting
Gilead (GILD) Gears Up to Report Q1 Earnings: What to Expect?
•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.